Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 8/20 | 0.50 |
| ▸ | DHFR | P00374 | 7/20 | 0.50 |
| ▸ | NCF1 | P14598 | 5/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.43 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154579 | 0.87 | DCPS (0.68) | DCPSDHFRNCF1KCNH2CSNK1A1 | |
| SCHEMBL29041258 | 0.86 | NCF1 (0.52) | DCPSDHFRNCF1KCNH2CSNK1A1 | |
| SCHEMBL3023761 | 0.78 | TLR7 (0.50) | DCPSNCF1TLR7NUDT1 | |
| SCHEMBL19678154 | 0.77 | L3MBTL1 (0.38) | DCPSDHFRNCF1 | |
| Hydrochloric Acid SCHEMBL3231113 | 0.77 | TLR7 (0.49) | DCPSNCF1TLR7NUDT1 | |
| SCHEMBL31187500 | 0.75 | DCPS (0.73) | DCPSDHFRKCNH2 | |
| SCHEMBL11402370 | 0.75 | DCPS (0.73) | DCPSDHFRKCNH2 | |
| SCHEMBL15284417 | 0.72 | CSNK1A1 (0.74) | DCPSDHFRKCNH2CSNK1A1CSNK1D | |
| SCHEMBL27248697 | 0.72 | NCF1 (0.44) | DCPSDHFRNCF1 | |
| SCHEMBL27248810 | 0.72 | NCF1 (0.44) | DCPSDHFRNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | US | disclosed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | disclosed |
| US-8507656-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| EP-2247305-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009097325-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| EP-1922337-A2 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | Amgen Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007027713-A2 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | AMGEN INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | TEK, VEGFA, THPO | DCPS 1631/4885DHFR 1486/4885NCF1 1500/4885 |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | TEK, VEGFA, THPO | DCPS 1631/4885DHFR 1486/4885NCF1 1500/4885 |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | TEK, VEGFA, THPO | DCPS 1631/4885DHFR 1486/4885NCF1 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.